each patient was evaluated in the acute ( 0-5 days ) and subacute ( 6-17 days ) phases by ( 1 ) clinical neurologic examination , ( 2 ) ct scans , and ( 3 ) n-isopropyl-p-123i-iodoamphetamine ( 123imp ) single-photon emission ct ( spect ) scans .
C0220825
evaluated
C0031809
clinical